Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VHL | P40337 | 12/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | NEK1 | Q96PY6 | 5/20 | 0.34 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.34 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.34 |
| ▸ | ELOC | Q15369 | 1/20 | 0.32 |
| ▸ | ELOB | Q15370 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22526852 | 0.83 | VHL (0.47) | VHLP2RX3P2RX2ELOCELOB | |
| SCHEMBL17947426 | 0.83 | VHL (0.48) | VHLALDH1A1P2RX3P2RX2 | |
| SCHEMBL21458942 | 0.82 | VHL (0.52) | VHLALDH1A1P2RX3P2RX2 | |
| SCHEMBL22955082 | 0.82 | VHL (0.46) | VHLP2RX3P2RX2ELOCELOB | |
| SCHEMBL20425319 | 0.82 | VHL (0.52) | VHLALDH1A1P2RX3P2RX2 | |
| SCHEMBL19600903 | 0.82 | VHL (0.46) | VHLP2RX3P2RX2ELOCELOB | |
| SCHEMBL24440245 | 0.81 | VHL (0.47) | VHLP2RX3P2RX2ELOCELOB | |
| SCHEMBL24440260 | 0.81 | VHL (0.47) | VHLP2RX3P2RX2ELOCELOB | |
| SCHEMBL22525599 | 0.81 | VHL (0.58) | VHL | |
| SCHEMBL25906660 | 0.80 | ALDH1A1 (0.34) | VHLALDH1A1NEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024064328-A1 | COMPOUNDS AND COMPOSITIONS AS SMARCA2/4 DEGRADERS AND USES THEREOF | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2024-03-28 | — | — | WO | disclosed |
| WO-2023220425-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| US-20230312542-A1 | HYDROXYPYRROLIDINE DERIVATIVE AND MEDICINAL APPLICATION THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-10-05 | — | — | US | disclosed |
| US-20230312542-A1 | HYDROXYPYRROLIDINE DERIVATIVE AND MEDICINAL APPLICATION THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-10-05 | — | — | US | disclosed |
| US-11746120-B2 | Stat degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| EP-4129402-A1 | HYDROXYPYRROLIDINE DERIVATIVE AND MEDICINAL APPLICATION THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2023-02-08 | — | — | EP | disclosed |
| WO-2022100710-A1 | TYROSINE KINASE 2 (TYK2) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI) , INC. (CN) | 2022-05-19 | — | — | WO | disclosed |
| WO-2021252666-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2021-12-16 | — | — | WO | disclosed |
| WO-2021236695-A1 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | MONTELINO THERAPEUTICS, INC. (US) | 2021-11-25 | — | — | WO | disclosed |
| WO-2021222114-A1 | BCL-2 PROTEIN INHIBITORS | RECURIUM IP HOLDINGS, LLC (US) | 2021-11-04 | — | — | WO | disclosed |
| WO-2020206424-A1 | STAT DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-10-08 | — | — | WO | disclosed |
| US-10787443-B2 | RAF-degrading conjugate compounds | ZAMBONI CHEM SOLUTIONS INC. (CA) | 2020-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11746120-B2 | Stat degraders and uses thereof | STAT4, STAT1, STAT3 | VHL 600/4885ALDH1A1 2465/4885NEK1 1875/4885 |
| US-20230312542-A1 | HYDROXYPYRROLIDINE DERIVATIVE AND MEDICINAL APPLICATION THEREOF | VHL, MDM2, NEDD4 | VHL 1/4885ALDH1A1 2395/4885NEK1 1151/4885 |
| US-10787443-B2 | RAF-degrading conjugate compounds | BRAF, RAF1, ARAF | VHL 11/4885ALDH1A1 273/4885NEK1 1323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.